CHD5 Inhibitors

The class of CHD5 Inhibitors is characterized by its capacity to interfere with the chromatin remodeling functions of the CHD5 protein. These compounds achieve this through a variety of mechanisms, primarily revolving around the modulation of histone post-translational modifications and chromatin structure.Compounds such as 5-Azacytidine, Trichostatin A, Vorinostat, Romidepsin, and Mocetinostat can directly modify the acetylation or methylation status of histones. These modifications can affect the conformation of chromatin and the accessibility of DNA, thus influencing the ability of CHD5 to interact with and remodel chromatin.

In a similar vein, JQ1 and I-BET762, inhibitors of BET bromodomains, can modulate the recognition of acetylated histones. These compounds can thereby impact the interaction of chromatin remodeling proteins, including CHD5, with chromatin. Additionally, compounds like EPZ-6438, GSK126, UNC1999, and DZNep, which are inhibitors of the histone methyltransferase EZH2, can modify histone methylation status. Such alterations can influence the chromatin structure and the associated activities of CHD5. Lastly, BIX-01294, an inhibitor of G9a and GLP histone methyltransferases, can affect histone methylation, thereby influencing the activity of CHD5.